Nicos A. Petasis

University of Southern California — United States

Chemistry · Physical Sciences

85h-index23.9kcitations330works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Synthetic Organic Chemistry Methods(56), Fatty Acid Research and Health(40), Immune Response and Inflammation(31), Chemical Synthesis and Analysis(31), Eicosanoids and Hypertension Pharmacology(30)

Publications325 total

On the Total Synthesis of 7,8(S,S)-Epoxy-17(S)-hydroxy-4(Z),9(E),11(E),13(Z),15(E),19(Z)-docosahexaenoic Acid Derivative
Molecules·2025Open Access
Synthon-based ligand discovery in virtual libraries of over 11 billion compounds
UNC Libraries·2024Open Access
Supplementary Figure S5 from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
2023Open Access
Supplementary Figure S5 from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
2023Open Access
Supplementary Figure 3 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
Supplementary Figure S2 from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
2023Open Access
Supplementary Figure 1 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
Supplementary Figure 2 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
Supplementary Figure S2 from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
2023Open Access
Data from The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models
2023Open Access
Supplementary Figure 1 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
Supplementary Figure S4 from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
2023Open Access
Supplementary Figure S1 from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
2023Open Access
Supplementary Tables from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
2023Open Access
Supplementary Figure 2 from The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models
2023Open Access
Supplementary Figure 3 from The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models
2023Open Access
Supplementary Figure 3 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
Supplementary Figure S4 from NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment
2023Open Access
Supplementary Materials and Methods from The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models
2023Open Access
Supplementary Figure 1 from The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models
2023Open Access
page 1 of 17Next →

Frequent Co-authors

Charles N. Serhan(29), Rong Yang(8), Makoto Arita(5), Nan Chiang(5), Hugh R. Brady(5), Jesmond Dalli(5), Song Hong(4), Sean P. Colgan(4), Clary B. Clish(4), Jeremy W. Winkler(4), Catherine Godson(3), Min Zhu(3), Jasim Uddin(3), Ilia A. Zavialov(3), Bruce D. Levy(3), Thomas E. Van Dyke(3), Tomoko Takano(3), Jane F. Maddox(3), Romain A. Colas(3), Karsten Gronert(3)